Acute Myeloid Leukemia Therapeutics Market Key Players : Eli Lilly and Company, Genzyme Corporation, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Celegene Corporation, Cephalon, Inc., and Eisai Inc.

Acute myeloid leukemia (AML), is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also start in other types of blood-forming cells. In AML, there is a fast production of the abnormal WBCs that get accumulated in the bone marrow, and affect the production of normal blood cells.

Key players profiled in the report include Eli Lilly and Company, Genzyme Corporation, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Celegene Corporation, Cephalon, Inc., and Eisai Inc.

Get Sample PDF Brochure : https://www.alliedmarketresearch.com/request-toc-and-sample/3721

The major factors that drive the market growth include advantages of biopharmaceuticals over conventional medicines, rise in geriatric population, unhealthy lifestyle, strong biopharmaceutical pipeline, and development of combination therapies that can treat diseases that were previously untreated. However, high cost of the therapeutic process, and its safety concerns, is expected to hinder the growth of the market. Moreover, ongoing researches have led to discovery of more efficient therapies for cancer treatment, which pose attractive opportunities for the key market players.

The global acute myeloid leukemia therapeutics market is segmented on the basis of treatment type and geography. According to treatment type, the market is divided into cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the market by type elucidates the regional trends.
• Key players and their strategies are analyzed to understand the competitive outlook of the market.

Acute Myeloid Leukemia Therapeutics Market Key Segments:

By Treatment Type

• Cytarabine
• Anthracycline Drugs

o Daunomycin
o Idarubicin
o Mitoxantrone
• Alkylating Agents

• Anti-Metabolites
• Tyrosine Kinase Inhibitors

o Dasatinib (Sprycel)
o Imatinib (Gleevec)

• Hormonal Therapy
• Others

By Region

• North America
o U.S.
o Canada
o Mexico

• Europe

o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe

• Asia-Pacific

o China
o India
o Japan
o Rest of Asia-Pacific

• LAMEA

o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.